




Bern
Berne

15. – 17. Mai
15 – 17 mai



39

Donnerstag, 16. Mai 2019

Bellavista 2, 6. OG

08:30 - 10:00

SGT

Freie Mitteilung

Clinical works I


Vorsitz: Patrick Dorn (Bern), Sven Hillinger (Zürich)

-
- 1 Stage IIIA should be divided in two different subgroups according to n and t stage in patients with resected lung cancer: Validation with another center database
N. Citak^{1,2}, L. Guglielmetti¹, Y. Aksoy², O. Isgörücü², M. Metin², A. Sayar², I. Opitz¹, D. Schneider¹, W. Weder¹, I. Inci¹, Presenter: N. Citak^{1,2} (¹Zürich, ²Istanbul/TR)
-
- 2 A novel combination strategy to treat KRAS-mutant lung cancer
R.-W. Peng, S.-Q. Liang, E. D. Bühler, S. Berezowska, T. M. Marti, L. Froment, H. Yang, S. R. Hall, E. Vassella, Z. Yang, G. J. Kocher, M. J. Amrein, C. Riether, A. F. Ochsenbein, R. A. Schmid, Presenter: D. Xu (Bern)
-
- 3 Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma
O. Lauk, M. Patella, M. Friess, T. Frauenfelder, D. L. Nguyen-Kim, S. Hillinger, I. Inci, W. Weder, I. Opitz, Presenter: M. Patella (Zurich)
-
- 4 Low dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of malignant pleural mesothelioma
S. Cavin, J. Faget, A. Gkasti, Y. Hao, E. Meylan, J. Y. Perentes, Presenter: S. Cavin (Lausanne)
-
- 5 Evaluation of feasibility and toxicity of irradiation combined with cisplatin-fibrin administration after lung sparing surgery in an orthotopic immunocompetent rat model for malignant pleural mesothelioma
O. Lauk, M. Kirschner, M. Meerang, K. Furrer, I. Grgic, V. Orłowski, F. Tschanz, M. Pruschy, I. Opitz, Presenter: K. Furrer (Zurich)
-
- 6 Chest wall resections and reconstructions for malignant diseases: A single center experience in 158 cases
L. Elahi-Rausis, E. Abdelnour, M. Gonzalez, D. Hasselbach, T. Krueger, W. Raffoul, H.-B. Ris, J. Y. Perentes, Presenter: L. Elahi-Rausis (Lausanne)
-
- 7 The co-expression of CD26 and TGF-β1 renders lung cancer targetable to CD26-inhibition
N. Enz¹, F. Janker², S. Andreoli², C. Opelz², W. Weder², J. H. Jang², W. Jungraithmayr¹, Presenter: W. Jungraithmayr¹ (¹Rostock/DE, ²Zurich)
-
- 8 Outcome of incidental and secondary bronchogenic carcinoma following lung transplantation
C. Forster, A. Koutsokera, J. D. Aubert, M. Gonzalez, T. Krueger, J. Y. Perentes, E. Abdelnour-Berchtold, Presenter: C. Forster (Lausanne)
-



Bern
Berne

15. – 17. Mai
15 – 17 mai



9

Increased mitochondrial mass is associated with cisplatin resistance and pemetrexed sensitivity in non-small cell lung cancer cells

T. M. Marti, Y. Gao, P. Dorn, S. Liu, H. Deng, R. W. Peng, S. R. Hall, G. Kocher, R. A. Schmid, Presenter: Y. Gao (Bern)

Die Vortragszeiten betragen 7 Minuten gefolgt von 2 Minuten Diskussion. / Die Abstracts Nr. 39.1 und 39.2 sind in der Endauswahl für den SGC-Preis der besten Erstpräsentation.